Perrey David A, Gilmour Brian P, Thomas Brian F, Zhang Yanan
Research Triangle Institute , Research Triangle Park, North Carolina 27709, United States.
ACS Med Chem Lett. 2014 Mar 25;5(6):634-8. doi: 10.1021/ml4004759. eCollection 2014 Jun 12.
Cannabinoid CB1 and orexin OX1 receptors have been suggested to form heterodimers and oligomers. Aimed at studying these complexes, a series of bivalent CB1 and OX1 ligands combining SR141716 and ACT-078573 pharmacophores were designed, synthesized, and tested for activity against CB1 and OX1 individually and in cell lines that coexpress both receptors. Compound 20 showed a robust enhancement in potency at both receptors when coexpressed as compared to individually expressed, suggesting possible interaction with CB1-OX1 dimers. Bivalent ligands targeting CB1-OX1 receptor dimers could be potentially useful as a tool for further exploring the roles of such heterodimers in vitro and in vivo.
大麻素CB1受体和食欲素OX1受体被认为可形成异二聚体和寡聚体。为了研究这些复合物,设计、合成了一系列结合SR141716和ACT-078573药效基团的二价CB1和OX1配体,并分别测试了它们对CB1和OX1的活性以及在共表达这两种受体的细胞系中的活性。与单独表达相比,化合物20在共表达时对两种受体的效力均有显著增强,表明其可能与CB1-OX1二聚体相互作用。靶向CB1-OX1受体二聚体的二价配体可能作为一种工具,用于进一步探索此类异二聚体在体外和体内的作用。